Hims & Hers requires 6-month prepaid commitments for compounded semaglutide; Ro separates membership and medication costs with branded FDA-approved options. We normalize both structures over 12 months and compare plan terms, medication types, and value against PlexusDx.

Injections and oral dissolving tablets (ODTs) deliver the same medication differently. We compare pricing, user experience, efficacy evidence, and practical trade-offs across nine platforms offering both routes.

Rift does not publish pricing or plan details on its public website; a quote is issued after questionnaire completion. PlexusDx lists month-to-month rates at $189 for semaglutide and $289 for tirzepatide, with no membership fee and prepaid multi-month discounts available.

PlushCare charges $19.99/month membership plus $129 for an initial visit, but medication costs are external and variable. We break down what you actually pay without insurance.

Most telehealth providers offer compounded tirzepatide only as an injection. Oral options—sublingual tablets, lozenges, capsules—exist but remain the minority. This evidence-based comparison shows which platforms offer which route, at what price, and where the economics and logistics differ in 2026.

Medication-included GLP-1 programs charge one flat price for medication, provider visits, and shipping. Membership-only programs charge a separate monthly fee for services, and you pay for medication on top. We compare 12-month costs, billing clarity, and cost predictability across both models.

Advertised starting prices often land below $100, but ongoing medication, membership fees, and prepayment terms typically raise the effective monthly cost above that threshold.

Fifty410 charges $199/month for semaglutide and $399–$549 upfront for tirzepatide (3-month bundles). GobyMeds charges $299–$499 upfront for semaglutide (3-month bundles, dose-tiered) and $299/month for tirzepatide. We break down starter versus high-dose costs over 12 months.

Found's 12-month cash-pay semaglutide plan requires $2,028 upfront for a $169/month rate; Hims & Hers advertises $199/month with a 6-month $1,194 commitment. PlexusDx offers $189 month-to-month with no prepayment. Here's how the economics and service models compare.

MEDVi and OrderlyMeds both sell compounded GLP-1 programs with no membership fee, but they price them differently: MEDVi uses a lower first month followed by a higher refill rate, while OrderlyMeds posts one month-to-month rate and a discounted three-month starter. This post compares the published terms as of September 22, 2026.

MEDVi and BrightMeds price compounded GLP-1 injections in different shapes: MEDVi with a lower first month and a higher refill, BrightMeds with one landing-page rate per medication and optional 3-month packs. This post compares semaglutide and tirzepatide injections separately, covers dose and renewal conditions, and shows where PlexusDx fits.

10Rx's prepaid quarterly packages deliver the lowest per-month equivalent for compounded semaglutide and tirzepatide, but require upfront commitment. PlexusDx offers month-to-month flexibility and multi-month discounts. Here's what the structures cost over 12 months.

We attempted to compare Peak Wellness and Zealthy GLP-1 programs but could not verify Zealthy's pricing or terms at checkout. Here's what the available evidence shows and where it falls short.

Compare Semaglutide vs Phentermine: mechanism, FDA-approval status, weight-management evidence, side-effect profile, monthly cost, and the genetic variable u...

Compounded Tirzepatide vs Zepbound explained — pharmacology, regulatory status, dosing context, safety profile, pricing as of 2026, plus the upstream genetic...

Compounded Tirzepatide vs Mounjaro explained — pharmacology, regulatory status, dosing context, safety profile, pricing as of 2026, plus the upstream genetic...

A side-by-side editorial look at Compounded Semaglutide vs Wegovy: mechanism, FDA status, real-world cost, and the GLP-1 pathway genetics most providers don'...

Compare Compounded Semaglutide vs Ozempic: mechanism, FDA-approval status, weight-management evidence, side-effect profile, monthly cost, and the genetic var...

Sermorelin products differ in formulation, delivery method, and sourcing. Understanding clinical evidence, biomarker context, and provider guidance helps patients make informed decisions about growth hormone secretagogue therapy.

Zepbound and Rybelsus sit on opposite sides of a practical divide: a weekly injection versus a daily oral tablet. This overview, current as of April 2026, leads with the format difference, then compares molecules, indications, trial evidence, safety, cost, and the shared genetics beneath both.

Victoza reached patients in 2010; Zepbound is a newer dual-incretin molecule. This independent review sets liraglutide beside tirzepatide on receptor action, dosing cadence, FDA indications, trial history, and monthly cost, then examines the inherited pathway variants, FTO, MC4R, and TCF7L2, that shape metabolic biology regardless of which drug a provider chooses.

Zepbound and Trulicity are both Eli Lilly injections, yet they were built for different jobs: tirzepatide for chronic weight management, dulaglutide for type 2 diabetes. This independent review compares receptor mechanism, FDA labels, trial evidence, tolerability, and cost, then looks at the FTO genetics that sit upstream of either choice.

Victoza is one of the earliest daily GLP-1 agonists; Zepbound is a newer dual-agonist arrival. This independent review compares liraglutide and tirzepatide across a generational leap in incretin design, covering mechanism, approved uses, trial evidence, safety, cost, and the metabolic genetics both compounds ultimately share.

Trulicity and Zepbound are both Eli Lilly products, yet one is a GLP-1-selective agonist and the other a dual agonist. This independent review compares dulaglutide and tirzepatide across receptor design, FDA-approved uses, the trial record, safety, monthly cost, and the shared genetic pathways beneath both molecules.

Rybelsus and Zepbound sit on opposite sides of a pharmacological line: GLP-1-selective semaglutide versus dual-incretin tirzepatide. This comparison covers receptor design, diverging FDA indications, trial programs, tolerability, price bands, and the shared genes upstream of either choice, plus practical guidance on reading the head-to-head evidence carefully.

Wegovy and Mounjaro are frequently paired in the same sentence, yet they are different molecules carrying different FDA labels. This editorial comparison walks through mechanism, approvals, trial evidence, safety, and cost, then turns to the shared genetic biology underneath any GLP-1 pathway decision.

New to the topic? This plain-language overview explains what Victoza and Ozempic actually are, how they relate as Novo Nordisk GLP-1 agonists, what their labels and trials cover, roughly what they cost, and why your own genetics frame the whole decision before any prescription is written.

Ozempic and Rybelsus are both semaglutide but anchor different corners of the GLP-1 market. This overview places them in the wider brand map, contrasts weekly injection with daily tablet, reads the trial evidence carefully, and covers indications, cost bands, and shared genetics.

This independent overview places Ozempic and Zepbound on the incretin agonist spectrum, running from single to dual to investigational triple targets, and covers FDA approvals, the trial programs, class-wide safety, the list-price band, and the genetics that precede any prescription decision.

This molecule-level comparison of Wegovy and Mounjaro centers semaglutide against tirzepatide, traces the incretin class approval timeline, walks through the trial programs, frames class-wide safety and the April 2026 list-price range, and grounds the whole picture in the shared upstream genetics that apply to either compound.